LOXL2 and diabetic kidney disease: Collectively, these findings establish endothelial LOX/LOXL2 as core regulators of pathogenic glomerular signaling in diabetes and position Verbascoside as an enzymatically targeted precision therapy for DKD acting through the disruption of this specific LOX/LOXL2-mediated axis.